Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Franco Carabello

Thoracic Surgery (Cardiothoracic Vascular Surgery) Tulsa, OK Doctor of Osteopathy

NPI 1245390863 CMS profile 1081983

717 S Houston Ave Ste 400, Tulsa, OK 74127

Open in the dashboard

General payments

$13,498

302 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Franco Carabello of Tulsa, OK is reported in the CMS Open Payments database as having received $13,498 across 302 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $997 24
2024 General $1,509 35
2023 General $2,156 63
2022 General $2,538 70
2021 General $1,263 33
2020 General $872 23
2019 General $4,162 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Franco Carabello
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to John Franco Carabello were reported at $997. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year John Franco Carabello Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $4,162 $886 $178–$3,167 $163
2020 $872 $341 $108–$1,605 $114
2021 $1,263 $453 $125–$1,886 $132
2022 $2,538 $695 $180–$2,566 $149
2023 $2,156 $745 $205–$2,662 $160
2024 $1,509 $799 $214–$2,967 $164
2025 $997 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Atricure, Inc. $2,351 27 payments
  2. Edwards Lifesciences Corporation $1,584 23 payments
  3. Boston Scientific Corporation $1,518 42 payments
  4. Abiomed $1,302 20 payments
  5. CryoLife, Inc. $857 7 payments
  6. Abbott Laboratories $821 13 payments
  7. Janssen Pharmaceuticals, Inc $636 27 payments
  8. Aziyo Biologics, Inc. $504 4 payments
  9. W. L. Gore & Associates, Inc. $480 6 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $446 18 payments
  11. Other $2,999 115 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,071 292 payments
  2. Travel and Lodging $2,355 9 payments
  3. Education $71 1 payment
Products named General payments · program years 2019–2025
  1. Edwards SAPIEN 3 Transcatheter Heart Valve $1,101 18 payments
  2. Impella $804 12 payments
  3. XARELTO $636 27 payments
  4. General - Therapies $620 13 payments
  5. On-X $571 1 payment
  6. ATRICLIP LAA EXCLUSION SYSTEM $526 7 payments
  7. LifeVest $446 18 payments
  8. VERQUVO $394 23 payments
  9. ECM Patch,Pouch $366 3 payments
  10. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $343 4 payments
  11. Other $7,063 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$54,289

Medicare's payments for the services billed

Medicare patients

121

Average age 73

Services billed

235

50 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 54%
Arthritis 54%
Chronic kidney disease 51%
Diabetes 49%
Atrial fibrillation 36%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $73
$73 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $56
$56 — —
Wegovy
  • Novo Nordisk Inc $19
$19 — —
Repatha
  • Amgen Inc. $17
$17 — —
VYNDAQEL
  • PFIZER INC. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

302 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record